SYK - Stryker Corp

NYSE · Healthcare · Medical Devices

$312.20

Market Closed

End of day · Jun 12, 2026, 12:00 AM

Active

Resolved

Bull

Bear

About

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

https://www.stryker.com

SYK - Stryker Corp

Healthcare

SYK has been on a wild ride this past year. It hit above 400 just last summer, then basically trended down for months, with some nasty dips, especially this spring. That last leg down from around 340 in April to sub 300 in May was rough. Seeing it now hover around 316, it feels like a lot of the panic is probably in the price. Not exactly the timing anyone dreams of, but here we are. I’m leaning bullish from here. Stryker still has a solid pipeline, especially with elective procedures and hospital CapEx starting to pick back up. The company’s execution has always stood out, and the demographic tailwind isn’t going away joint replacements and robotics are still long term growth drivers. If hospital budgets are normalizing (and recent management commentary suggested as much), their end markets could start looking a lot less soft over the next couple quarters. I’m targeting 372.00 over the next 8 weeks. That lines up with the upper range of where it traded a few months ago, before the selloff got vicious. It’s not a hail mary moonshot, just a retrace to a more reasonable multiple if you figure growth picks back up. To get there, I’m expecting at least one solid earnings print or upbeat guidance to break this dead money trend. The risk is pretty obvious: if hospital spending disappoints, or Stryker guides down again, the stock can easily retest the lows. Plus, if margin pressure shows up in the next report, you’re back in the penalty box. Not pretending there’s no risk, just think the risk/reward makes sense here with most of the recent pain already priced in.

Entry

$316.48

Above

$372.00

Jul 21, 2026

Karma

125 to 17562

Bullish

Open

Vote